Drug Search Results
More Filters [+]

Emedastine

Alternative Names: emedastine, emadine
Latest Update: 2023-04-28
Latest Update Note: News Article

Product Description

Emedastine is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell/basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Emedastine)

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Transdermal,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Malaysia | Morocco | Netherlands | Norway | Pakistan | Philippines | Poland | Portugal | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Hisamitsu
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Emedastine

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Rhinitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-183844

P2

Active

Rhinitis, Allergic

None

Recent News Events